AC Immune (ACIU)
(Delayed Data from NSDQ)
$3.06 USD
-0.17 (-5.26%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $3.06 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.06 USD
-0.17 (-5.26%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $3.06 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of -159.52% and 99.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
by Zacks Equity Research
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
by Zacks Equity Research
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
by Kinjel Shah
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
by Zacks Equity Research
Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
by Zacks Equity Research
The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.
Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does AC Immune (ACIU) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Small-Cap Stocks to Play the January Effect
by Sweta Killa
Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.
AC Immune (ACIU) Upgraded to Buy: Here's Why
by Zacks Equity Research
AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity
by Zacks Equity Research
Biogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog.
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
by Ekta Bagri
The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.
Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and AC Immune (ACIU) have performed compared to their sector so far this year.
Are Medical Stocks Lagging AC Immune (ACIU) This Year?
by Zacks Equity Research
Here is how AC Immune (ACIU) and Exact Sciences (EXAS) have performed compared to their sector so far this year.
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AC Immune (ACIU) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Earnings Preview: Qiagen (QGEN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune (ACIU) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) Soars 8.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
NeoGenomics (NEO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why
by Zacks Equity Research
AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for neurodegenerative diseases.
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance
by Zacks Equity Research
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of 29.17% and 457.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
by Kinjel Shah
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.